Denise Scots-Knight has served as a member of the Elanco Board of Directors since March 2019. 

Scots-Knight serves as the CEO, board member and co-founder of Mereo BioPharma Group plc, an international biopharmaceutical company focused on rare diseases. Scots-Knight has more than 25 years of experience in the biopharmaceutical industry, working in research and development management and as a venture capitalist. Prior to co-founding Mereo BioPharma, Scots-Knight ran Phase4 Partners Ltd., a venture capital business that invested globally in biotechnology companies, having previously led the management buy-out of the business from Nomura. Scots-Knight ran Nomura's life sciences investment for 12 years before the MBO. She started her career in research and development management at Amersham and Fisons and as a senior executive at Scientific Generics. 

Scots-Knight has served on many United States and European boards including those of Viacell Inc., Idenix Pharmaceuticals, Nabriva Therapeutics, Albireo Pharma and Oncomed Pharma. Additionally, she has been named one of the 15 leading women in European biotech by Labiotech UG. Scots-Knight holds a Ph.D. from Birmingham University.